Fig 1.
Selection of Medicare patients diagnosed with primary pancreatic adenocarcinoma in 2007–2009.
Table 1.
Distribution of demographic, clinical and comorbid characteristics by statin treatment after diagnosis with pancreatic adenocarcinoma.
Table 2.
Description of statin use after cancer diagnosis by name, lipophilicity, potencity, intensity, duration, consistency of use (n = 2456).
Table 3.
Relative hazard of death for statin use after cancer diagnosis vs. no statin use (n = 7813).
Table 4.
Multivariable-adjusted association between statin use after diagnosis with pancreatic cancer and overall survival in substrata of covariates.
Table 5.
Multivariate association of survival with name, lipophilicity, potency, intensity of statin use after diagnosis of pancreatic adenocarcinoma.